Literature DB >> 12799553

Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children.

Ari Bitnun1, Etienne Sochett, Paul Babyn, Stephanie Holowka, Derek Stephens, Stanley Read, Susan M King.   

Abstract

OBJECTIVE: To determine the extent and degree of abnormalities of serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor (PI)-treated and PI-naive HIV-infected children.
DESIGN: A cross-sectional study involving HIV-infected children, 3-18 years of age, in a paediatric tertiary care centre. MAIN OUTCOME MEASURES: Total, HDL and LDL-cholesterol, triglycerides, glucose, insulin, proinsulin and C-peptide were determined in the fasting state. Insulin resistance was assessed using the homeostatic model assessment-insulin resistance (HOMA-IR). Abdominal adipose tissue distribution was determined by single-slice computed tomography at the umbilical level.
RESULTS: Thirty PI-treated and 20 PI-naive children were evaluated (76% prepubertal). PI-treated children had significantly higher total cholesterol (P = 0.0021), LDL-cholesterol (P = 0.019) and triglycerides (P = 0.0018). Serum glucose, insulin, proinsulin and C-peptide, the insulin : glucose ratio, HOMA-IR and abdominal adipose tissue distribution were similar in the two groups. Clinical and immunological HIV categories, viral load, CD4 cell count and stavudine therapy were not significantly associated with serum lipids, insulin resistance or abdominal adipose tissue distribution. The predictor variable most strongly associated with fasting serum insulin and HOMA-IR was the Tanner stage. Age was the most significant predictor variable of the visceral : subcutaneous adipose tissue ratio.
CONCLUSION: In this cohort of predominantly prepubertal HIV-infected children, PI therapy was associated with an atherogenic dyslipidemia but not with insulin resistance or abnormal abdominal adipose tissue distribution. The results suggest that children, particularly prepubertal children, are less susceptible than adults to PI-induced changes in glucose homeostasis and abdominal adipose tissue distribution.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12799553     DOI: 10.1097/00002030-200306130-00006

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  16 in total

1.  Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study.

Authors:  Denise L Jacobson; Kunjal Patel; George K Siberry; Russell B Van Dyke; Linda A DiMeglio; Mitchell E Geffner; Janet S Chen; Elizabeth J McFarland; William Borkowsky; Margarita Silio; Roger A Fielding; Suzanne Siminski; Tracie L Miller
Journal:  Am J Clin Nutr       Date:  2011-11-02       Impact factor: 7.045

2.  Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.

Authors:  Louise Kuhn; Ashraf Coovadia; Renate Strehlau; Leigh Martens; Chih-Chi Hu; Tammy Meyers; Gayle Sherman; Gillian Hunt; Deborah Persaud; Lynn Morris; Wei-Yann Tsai; Elaine J Abrams
Journal:  Lancet Infect Dis       Date:  2012-03-16       Impact factor: 25.071

3.  Clinical management and follow-up of hypercholesterolemia among perinatally HIV-infected children enrolled in the PACTG 219C study.

Authors:  Denise L Jacobson; Paige Williams; Katherine Tassiopoulos; Ann Melvin; Rohan Hazra; John Farley
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-15       Impact factor: 3.731

4.  Factors associated with insulin resistance among children and adolescents perinatally infected with HIV-1 in the pediatric HIV/AIDS cohort study.

Authors:  Mitchell E Geffner; Kunjal Patel; Tracie L Miller; Rohan Hazra; Margarita Silio; Russell B Van Dyke; William Borkowsky; Carol Worrell; Linda A DiMeglio; Denise L Jacobson
Journal:  Horm Res Paediatr       Date:  2011-10-26       Impact factor: 2.852

5.  Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.

Authors:  Ashraf Coovadia; Elaine J Abrams; Renate Stehlau; Tammy Meyers; Leigh Martens; Gayle Sherman; Gillian Hunt; Chih-Chi Hu; Wei-Yann Tsai; Lynn Morris; Louise Kuhn
Journal:  JAMA       Date:  2010-09-08       Impact factor: 56.272

6.  Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children.

Authors:  Katherine Tassiopoulos; Paige L Williams; George R Seage; Marilyn Crain; James Oleske; John Farley
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-15       Impact factor: 3.731

7.  Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1.

Authors:  Tracie L Miller; E John Orav; Steven E Lipshultz; Kristopher L Arheart; Christopher Duggan; Geoffrey A Weinberg; Lori Bechard; Lauren Furuta; Jeanne Nicchitta; Sherwood L Gorbach; Abby Shevitz
Journal:  J Pediatr       Date:  2008-06-09       Impact factor: 4.406

8.  Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy.

Authors:  Caroline J Chantry; Michael D Hughes; Carmelita Alvero; Joseph S Cervia; William A Meyer; Janice Hodge; Peggy Borum; Jack Moye
Journal:  Pediatrics       Date:  2008-06-02       Impact factor: 7.124

9.  Longitudinal changes in regional fat content in HIV-infected children and adolescents.

Authors:  Stephen M Arpadi; James Bethel; Mary Horlick; Moussa Sarr; Marukh Bamji; Elaine J Abrams; Murli Purswani; Ellen S Engelson
Journal:  AIDS       Date:  2009-07-31       Impact factor: 4.177

10.  Dyslipidemia and its Correlates among HIV Infected Children on HAART Attending Mbarara Regional Referral Hospital.

Authors:  Dorah Nampijja; Elias Kumbakumba; Francis Bajunirwe; Julius Kiwanuka
Journal:  Int Clin Pathol J       Date:  2017-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.